An interventional study of MoDIDol intervention in Autism Disorder, Multiple Disabilities and Pain, sponsored by University Hospital, Brest. Recruiting at 1 site in France. Open to participants aged Up to 24 Years. Per ClinicalTrials.gov, last updated 2025-12-24.
Sponsored by University Hospital, Brest · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies in Autistic Disorder with a site in France — 10 open to participants now, 10 under way, 1 of them phase 3. Autistic Disorder · France.
Among the 50 studies in Autistic Disorder with a site in France, this one is the 15th largest by planned enrollment of the 37 interventional ones that give a count, is one of 3 that started in 2025, is one of 26 with no phase, and was the 47th registered.
1,035 studies on the registry are indexed under Autistic Disorder; 270 are open to participants now.
Browse Autistic Disorder studies →10 of the 50 studies in Autistic Disorder with a site in France are open now. Recruiting first, the newest first:
Karuna Therapeutics, Inc., a Bristol Myers Squibb company · Sites in France, United States, Australia and 8 more countries
Ages 5–17
University Hospital, Grenoble · Sites in France
Ages 18–50 · Healthy volunteers
Centre Hospitalier Intercommunal Robert Ballanger · Sites in France
Ages 3–15
University Hospital, Tours · Sites in France
Ages 18+ · Healthy volunteers
Institut National de la Santé Et de la Recherche Médicale, France · Sites in France
Ages 24 mo–70 yrs · Healthy volunteers
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 184 Autistic Disorder studies recruiting now, 33 (18%) set no upper age limit and 144 (78%) stop at 75 or younger; 150 take children under 18; 56 take healthy volunteers.
This study: Up to 24 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is above the median of 50 across 814 interventional studies indexed under Autistic Disorder.
Median enrollment 60 across the 37 interventional studies, 103 across the 13 observational. Of the 32 that completed or were terminated, 4 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 50 have an industry lead sponsor. The 10 most frequent:
University Hospital, Brest is the lead sponsor of 602 studies on the registry; 137 are open to participants now.
University Hospital, Brest has 4 studies filed under Autistic Disorder — fewer than ten, so there is no comparison to draw.
1 of the studies in Autistic Disorder with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06443320Centre Hospitalier Intercommunal Robert BallangerEvaluation of the Videodrama Therapeutic Device for Children with Autism Spectrum Disorders | 2027-03-04 |
Add it to your calendar (.ics) → With an account.
Among the 50 studies in Autistic Disorder with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Pain is described by patients with a Neurodevelopmental Disorder (NDD), including Autism Spectrum Disorder (ASD), Intellectual Development Disorder (IDD) or multiple disabilities, and the family as one of the main associated disorders; its management is also one of the main concerns of families and professionals. At present, there is no validated and tested pain management system in populations facing complex pain situations. In response to the lack of a pain management services, a multi-disciplinary mobile team was set up in September 2022 at the Brest University Hospital (Mobile Pain Handicap Team Intellectual Disability 0-25 years; MoDIDol). This team offers a specific protocol for the assessment and management of pain that takes into account the social and family environment, the living context and the clinical characteristics of patients (children, adolescents and young adults (0-25 years) with IDD, ASD or multiple disabilities). The team includes at least one paediatrician specialising in the assessment and treatment of pain and a nurse, and travels to patients' usual living environments.
The MoDIDol team intervenes at the request of parents or professionals in complex situations involving pain or behavioural problems suggestive of pain, unresolved despite previous treatment. Parents and professionals learn about the MoDIDol team through flyers and information provided by associations and organisations supporting people with disabilities (associations, CRDI, etc.).
Once they are included in the study and after consent has been signed, multidisciplinary follow-up consultations are carried out by the MoDIDol team for pain management (every 6 weeks).
At the same time, three data collection sessions are planned for the participants, 3 months apart. Questionnaires are completed at each point by dedicated study staff. Interviews are conducted at 6-month intervals among a representative sample of professionals and parents.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single arm study Interventions are : * parents education for NCCPC and PPP by a pain specialized nurse at T1 * parents fullfilling of questionnaires à T1, T2 and T3 with study engineer
Procedure: MoDIDol intervention
Multidisciplinary mobile intervention system specialising in pain management for patients with moderate to severe intellectual development disorders, isolated or associated with ASD or multiple disabilities. Treatment recommendations, pain assessment, training in scales, follow-up consultations every 6 weeks for 6 months, continued if the situation is not resolved, call at 12 months.
Global Clinical Improvement at 6 months
The primary outcome is the patient's global clinical improvement as perceived by family caregivers and/or institutional professionals, using the Patient Global Impression of Change (PGIC) scale after 6 months of care provided by the MoDIDol team. Improvement is defined as a PGIC score of 1 or 2 out of 7. scale from 1 to 7, higher scores mean worse outcome.
Time frame: From baseline to the end of 6 months of treatment with the MoDIDol system, assessed up to 6 months (T3)
Global Clinical Improvement at 3 months
Global clinical improvement of the patient, as reported by caregivers and/or professionals, measured using the Patient Global Impression of Change (PGIC) scale after 3 months of MoDIDol care. Improvement is defined as a PGIC score of or 2 out of 7. Scale from 1 to 7, higher scores mean worse outcome.
Time frame: From baseline to the end of 3 months of treatment with the MoDIDoL system, assessed up to 3 months (T2)
Non Communicating Children's Pain Checklist (NCCPC) Pain Intensity Scores at T1, T2, and T3
Pain intensity will be assessed using the french version of Non Communicating Children's Pain Checklist (NCCPC) scale at baseline (T1), 3 months (T2), and 6 months (T3). The full rating is based on a 90-point scale : 4-point scale (0 : not observed ; 3 : frequently) for 30 behavioral assessments. But some behaviors can be omitted when non applicable (NA). Pain is mild if score is between 6 and 10, and moderate to severe if score is 11 or more.
Time frame: Baseline (T1), after 3 months (T2), and 6 months (T3) of treatment with the MoDIDol system.
Pediatric Pain Profile (PPP) Pain Intensity Scores at T1, T2, and T3
Pain intensity will be assessed using the french version of Pediatric Pain Profile (PPP) scale at baseline (T1), 3 months (T2), and 6 months (T3). 20 behaviors are to be rated from 0 = not at all to 3 = completely. Pain is moderate to severe if score is 14/60 or above.
Time frame: Baseline (T1), after 3 months (T2), and 6 months (T3) of treatment with the MoDIDol system.
Non Communicating Children's Pain Checklist (NCCPC) Pain Category Change
Patients will be categorized based on the french version of Non Communicating Children's Pain Chlecklist (NCCPC) (\<6 : no pain; 6 to10 : mild pain; \>10 : moderate to severe pain) scores to evaluate changes in pain category from T1 to T2 and T2 to T3. The full rating is based on a 90-point scale : 4-point scale (0 : not observed ; 3 : frequently) for 30 behavioral assessments. But some behaviors can be omitted when non applicable (NA). Pain is mild if score is between 6 and 10, and moderate to severe if score is 11 or more.
Time frame: Baseline (T1), after 3 months (T2), and 6 months (T3) of treatment with the MoDIDol system
Pediatric Pain Profile Pain Category Change
Patients will be categorized based on french version of Pediatric Pain Profile (PPP) (\<14; \> or =14) scores to evaluate changes in pain category from T1 to T2 and T2 to T3. Twenty behaviors are to be rated from 0 = not at all to 3 = completely. Pain is moderate to severe if score is 14/60 or above.
Time frame: Baseline (T1), after 3 months (T2), and 6 months (T3) of treatment with the MoDIDol system
Non Communicating Children's Pain Checklist (NCCPC) Pain Behavior Profiles
Behavioral indicators of pain will be documented using the item-based responses from Non Communicating Children's Pain Checklist (NCCPC) scale at T1. The full rating is based on a 90-point scale : 4-point scale (0 : not observed ; 3 : frequently) for 30 behavioral assessments. But some behaviors can be omitted when non applicable (NA). Pain is mild if score is between 6 and 10, and moderate to severe if score is 11 or more.
Time frame: Baseline (T1)
Pediatric Pain Profile Pain Behavior Profiles
Behavioral indicators of pain will be documented using the item-based responses from Pediatric Pain Profile (PPP) scale at T1. Behaviours are to be assessed from 0 = not at all to 3 = completely (score from 0 to 60; pain if score \> 14).
Time frame: Baseline (T1)
Behavioral Disturbance Evolution
Frequency (0:never to 4: At least once an hour) and severity (1: mild to 3: severe) of three types of behaviors (self-injurious behaviors, stereotypical behaviors, and aggressive/destructive behaviors) will be assessed with the Behavior Problems Inventory (BPI) scale at T1, T2, and T3.
Time frame: Baseline (T1), after 3 months (T2), and 6 months (T3) of treatment with the MoDIDol system.
PedsQL Patient Quality of Life Scores
Quality of life will be assessed using Pediatric Quality of Life Inventory (PedsQL) for patients without profound disabilities on a five-point Likert scale (from 0: Never/Bad; to 4: Almost Always/Excellent) for 15 items at T1, T2, and T3.
Time frame: Baseline (T1), after 3 months (T2), and 6 months (T3) of treatment with the MoDIDol system
PolyQoL Patient Quality of Life Scores
Quality of life will be assessed using Quality of Life Scale for People with polyhandicap (PolyQoL) for patients with profound multiple disabilities on a five-point Likert scale (from 1: very bad; to 5: very goodt) for 21 items at T1, T2, and T3.
Time frame: Baseline (T1), after 3 months (T2), and 6 months (T3) of treatment with the MoDIDol system
Sleep Quality Scores
Sleep disorders will be measured with the Sleep Disturbance Scale for Children (SDSC) scale on a five-point Likert scale (from 1: never; to 5: every day) for 25 items at T1, T2, and T3.
Time frame: Baseline (T1), after 3 months (T2), and 6 months (T3) of treatment with the MoDIDol system
Parental Quality of Life
Parental quality of life will be assessed using the World Health Organization Quality of Life (WHOQOL-BREF) across four domains rated on a 5-point Likert scale (score from 1 to 5) for 26 items at T1, T2, and T3.
Time frame: Baseline (T1), after 3 months (T2), and 6 months (T3) of treatment with the MoDIDol system
Parental Stress
Parental stress will be evaluated using the Parenting Stress Index (PSI-4) at T1, T2, and T3. This questionnaire includes 120 items divided in two categories (stressors associated with the child domain, or with de parent domain) rated on a 5-point Likert scale ranging from "strongly disagree" to "strongly agree". The total score of stress is obtained by adding up the results. The higher the value is, the higher the stress.
Time frame: Baseline (T1), 3 months (T2), and 6 months (T3)
Determinants of Success
Individual (e.g., diagnosis, development level, sensory profile) and environmental (e.g., living environment, type of care) factors will be analyzed in relation to PGIC (Patient Global Impression of Change) score at T3.
Time frame: From baseline to the end of 6 months of treatment with the MoDIDol system, assessed up to 6 months (T3)
Pain Mechanism, Localization, and Etiology
Pain causes will be described according to the mechanism (nociceptive, neuropathic, nociplastic), location, and etiology. Patients with intellectual deficiency are not able to describe their pain because of verbal impairment. Qualitative informations are available through parents and professionnal observations. Evaluation is based on physical examination, specialized medical advice (dental, ENT, ...) and additional examinations, such as laboratory or medical imaging, if needed. These description are build at T1 as hypothesis and may be specified depending on developments during treatment.
Time frame: Pain mechanism, location and etiology are determined at T1 but can be revised during the 6 months patient follow up
Analgesic and Behavioral Treatments
Description of treatments (indication and dosage) for pain and behavior at T2 and T3.
Time frame: From baseline to the end of 3 months (T2) and 6 months (T3) of treatment with the MoDIDol system
Psychometric Properties of Non Communicating Children's Pain Checklist (NCCPC) Scale
Internal consistency and structural validity of the french version of Non Communicating Children's Pain Checklist (NCCPC) (for patients with ASD) scale will be assessed.
Time frame: Through study completion, an average of 6 months after baseline.
Psychometric Properties of Pediaric Pain Profile Scale
Internal consistency and structural validity of the french version of Pediatric Pain Profile (PPP) scale will be assessed.
Time frame: Through study completion, an average of 6 months after baseline.
Qualitative Interviews with Parents and Professionals
Impact of MoDIDol will be assessed through semi-structured interviews before (T1) and after (T3) of the intervention. Themes include daily impact of pain, beliefs, use of pain assessment tools, and perceived value of the mobile team
Time frame: Baseline (T1) and after 6 months (T3) of treatment with the MoDIDol system
Plan to share: Yes — All collected data that underlie results in a publication
Supporting information: Study protocol
Time frame: Data will be available after the publication of result and ending fifteen years following the last visit of the last patient
Access criteria: Data access requests will be reviewed by the internal committee of Brest UH. Requestors will be required to sign and complete a data access agreement.
No publications or documents are linked to this record.
Started Oct 2025 (actual). Primary completion is estimated for Apr 2028, 30 months after the start.
Of 355 non-industry interventional studies with no phase under Autistic Disorder, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's planned 30 months is above that.
Counting every sponsor, half of 367 studies reached it within 26 months; a quarter within 13 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.